item management s discussion and analysis of results of operations  and liquidity and capital resources a results of operations the following table summarizes the company s historical results of operations as a percentage of revenues for fiscal years  and fiscal year ended amount percent amount percent amount percent dollars in thousands ethex generic products    kv manufacturing and licensing    pdi pharmaceutical compounds    net revenues    costs and expenses manufacturing costs    research and development    selling and administrative    other  net  total costs expenses    income before income taxes    net income    fiscal compared to fiscal revenues 
net revenues increased million  or  to million during fiscal from million in fiscal this sales growth was primarily due to an increase in the volume of new and existing products sold by ethex and particle dynamics  partially offset by lower contract services sales 
net revenues from ethex increased million  or  to million during fiscal from million in fiscal this increase was primarily due to the launch of twelve new generic products during fiscal  in addition to increased sales of products introduced in prior years 
net revenues derived from the sale of specialty pharmaceutical raw materials by pdi increased million  or  to million during fiscal this increase was attributable to the increased sales volumes related to the introduction of new products for the over the counter descote r and destab tm product lines 
as expected  contract services revenues decreased 
million  or  to million in fiscal from million in fiscal which is attributable to reduced sales volume 
while the company anticipates continued growth in sales of the products it markets  there are no assurances that the annual percentage rate of sales growth will continue at past levels 
costs and expenses 
manufacturing costs increased million  or  to million during fiscal from million in fiscal due to increased volume 
manufacturing costs as a percentage of revenues increased to from primarily due to the change in the mix of products sold and the effect of the competitive pricing in the generic pharmaceutical industry 
research and development costs increased 
million  or  to million during fiscal from million in fiscal this increase was due to higher personnel  raw material and clinical costs 
the company expects to continue spending for research and development in the future  emphasizing the development of additional products for sale by ethex  new branded products and new drug delivery technologies 
selling and administrative expenses increased million  or  to million during fiscal from million in fiscal as a percentage of revenue  selling and administrative expenses decreased to from 
the increase in selling and administrative expenses was primarily related to the company s selling and promotional activities associated with the significant growth experienced in the sales of new and existing products marketed by ethex and particle dynamics  and additional personnel to support the company s continued growth 
income taxes were provided at an effective rate of in fiscal compared to in fiscal the increase is attributable to the utilization of loss carry forwards generated in prior years during fiscal no loss carryforwards were available in fiscal net income 
as a result of the factors described above  net income improved million  or  to million for fiscal from net income of million in fiscal compared to fiscal revenues 
net revenues increased million  or  to million during fiscal from million in fiscal this sales growth was primarily due to an increase in the volume of new and existing generic products sold by ethex  increased licensing revenues and volume in contract services and particle dynamics 
net revenues from ethex increased million  or  to million during fiscal from million in this increase was primarily due to the launch of ten new generic products during fiscal  in addition to increased sales of products introduced in the prior year 
net revenues derived from the sale of specialty pharmaceutical raw materials by pdi increased 
million  or  to million during fiscal this increase was attributable to the increased sales volumes related to the prior years introduction of new products for the over the counter descote r and destab tm product lines 
contract services and licensing revenues increased million  or  to million in fiscal from million in fiscal  primarily due to increased licensing revenues from an agreement concluded with roche holding  ltd 
costs and expenses 
manufacturing costs increased million  or  to million during fiscal from million in fiscal manufacturing costs as a percentage of revenues decreased to from 
this percentage decrease was primarily due to the continued growth in sales of higher margin products by ethex and increased margins in the contract manufacturing business 
research and development costs increased 
million  or  to million during fiscal from million in fiscal this increase was due to higher personnel costs 
selling and administrative expenses increased million  or  to million during fiscal from million in fiscal however  as a percentage of revenue  selling and administrative expenses decreased to from 
the increase in selling and administrative expenses was primarily related to the company s selling and promotional activities associated with the significant growth experienced in the sales of new and existing generic products marketed by ethex and additional personnel to support the company s continued growth 
other  net decreased million  or  to 
million during fiscal from million in fiscal this was primarily attributable to increased interest income of 
million as a result of interest earned on increased average daily cash balances  decreased interest expense of million as a result of lower effective interest rates as well as lower levels of average borrowing and reduced amortization cost 
the tax provision of  for fiscal was for state income taxes  while the  in was due to the effect of the alternative minimum tax 
net income 
as a result of the factors described above  net income improved million  or  to million for fiscal from million in fiscal b year readiness the company s computer systems  software and related technologies are affected by the year compliance issue 
the company has been identifying and correcting affected applications to ensure that all of its key computer systems will be year compliant by early  and has also been working with its vendors and suppliers to ensure their compliance 
costs to modify such applications have been  and are estimated to remain  immaterial to the company s results of operations or financial condition 
c liquidity and capital resources the following table sets forth selected balance sheet data and ratios for fiscal years  and at march  in s working capital ratio to to to quick ratio to to to debt to debt plus equity 
to 
to 
to total liabilities to equity 
to 
to 
to cash and cash equivalents    working capital    long term liabilities    shareholders equity    working capital for fiscal increased million  or  to million due primarily to the company s net income in net cash provided by operating activities for fiscal included increases in receivables of million and inventories and other current assets of million to improve service levels  which resulted primarily from increased sales volume of ethex products  and an increase in accounts payable and accrued liabilities of million 
these changes in receivables  inventories and payables of million combined with net income and non cash charges aggregating million  resulted in cash provided by operating activities of million for fiscal  an improvement of million or 
at the end of fiscal  the company s quick assets  cash  cash equivalents and accounts receivable increased million from the prior year  while current liabilities increased million  resulting in a quick ratio of to compared to to at the end of the increase in current liabilities is due primarily to an increase in accounts payable and accruals for salaries and benefits  income taxes and revenue sharing  all associated with increased sales and earnings 
the debt to debt plus equity and total liabilities to equity ratios for fiscal increased due to the addition of million in debt used for the purchase of a facility which was previously leased  and an adjacent facility 
investing activities in fiscal reflected capital expenditures in cash of million excluding the facility purchase which was financed with long term debt  and net expenditures for other assets of 
million  which were provided for through operations 
in january  the company concluded an agreement with a major pharmaceutical marketer whereby the company received million million of which was included in revenue and certain other considerations  plus million for the sale of certain class a common stock options exercisable in various periods through september see notes and 
the transaction was entered into between the parties in consideration for giving the marketing company the right to explore the company s drug delivery technologies and to replace certain other product agreements and to provide royalties and product opportunities 
in january  the company concluded a broad based agreement with roche holding ltd 
of basel  switzerland roche see notes and 
as part of the agreement  roche purchased  shares of common class a stock for million 
in addition  the agreement included cash payments of million made in january and  respectively  and one additional payment to be received in january  unless regulatory approval of a potential follow on product in the same therapeutic area is received prior to that date 
such payments have been included in revenue  and the last payment will be similarly treated when received 
upon marketing  kv would receive royalties on sales of the follow on product 
the company s cash and cash equivalents on hand at year end were million 
the company had in place at march   an unsecured credit facility aggregating million with lasalle national bank 
as of march   the company had no cash borrowings  however  million of open letters of credit were issued under the facility 
the company s capital equipment commitments at year end totaled approximately million 
although the company generally has been able to pass along to its customers at least a portion of cost increases in labor  manufacturing and raw materials under its agreements  in certain instances no increases have been effected due to market conditions 
it is not meaningful to compare changing prices over the past three years because the products  product formulas  product mix and sources of raw materials have varied substantially 
the company expects to continue a relatively high level of expenditures and investment for research  clinical and regulatory efforts relating to the development and commercialization of proprietary new products and advanced technology products and their approval for marketing 
the company believes funds generated from operating activities and existing cash  together with the funds available under its credit facility and funds provided from licensing agreements will be adequate to fund the company s short term needs 
d new accounting standards in  the financial accounting standards board fasb issued statement of financial accounting standards sfas no 
 earnings per share 
sfas no 
replaced the previously reported primary and fully diluted earnings per share with basic and diluted earnings per share 
unlike primary earnings per share  basic earnings per share excludes any dilutive effects of options  warrants and convertible securities 
diluted earnings per share is very similar to the previously reported fully diluted earnings per share 
all earnings per share amounts for all periods have been presented  and where necessary  restated to conform to the sfas no 
requirements 
in june  the fasb issued sfas no 
 reporting comprehensive income  which requires the reporting of comprehensive income and its components in the financial statements 
comprehensive income is defined as the change in equity from transactions and other events and circumstances from non owner sources  and excludes investments by and distributions to owners 
comprehensive income includes net income and other items of comprehensive income meeting the above criteria 
there is no impact on the company s financial statements due to the issuance of this statement 
in june  the fasb issued sfas no 
 disclosures about segments of an enterprise and related information 
sfas no 
is effective for fiscal years beginning after december  and requires reporting about operating segments  products and services  geographic areas and major customers 
its objective is to provide information about the different types of business activities and economic environments in which businesses operate 
the first disclosures will be required in the company s annual report 
the company does not expect substantial changes in its definition of segments 
in february  the fasb issued sfas no 
 employers disclosures about pensions and other postretirement benefits  which standardizes the disclosure requirements for pensions and other postretirement benefits and requires additional information on changes in the benefit obligations and fair values of plan assets that will facilitate financial analysis 
sfas no 
is effective for years beginning after december   and requires comparative information for earlier years to be restated  unless such information is not readily available 
the company has no pensions or postretirement benefit plans in place at this time 
there is no impact on the company s financial statements due to the issuance of this statement 

